Development of compounds for the prevention of Acute Kidney Injury
Sulfateq BV is an innovative biotechnology research company that is developing breakthrough compounds for the prevention of Acute Kidney Injury (AKI). Acute Kidney Injury is the sudden loss of kidney function and it affects more than 1.2 million people each year in the United States alone. It occurs in different situations and is particularly frequent in patients hospitalized for major surgery. Currently there is no therapy or drugs available for the protection against AKI during major surgery and we want to change this with our SUL-138 compound.
Our compounds emerged from research on hibernation and provide a new mechanism of action for cell protection, organ protection and prophylactic use and they have a huge potential to support drug development for AKI prevention. Currently our SUL compounds are in the final pre-clincal development phase. After the pre-clincal phase we will proceed with clinical trials, registration and finally market introduction. We see huge potential for the hibernation technology and its benefits for Acute Kidney Injury.
Other applications for our compounds
The main focus of SUL-138 is the prevention of Acute Kidney Injury (AKI) during cardiac surgery. But besides AKI SUL-138 also has multiple applications in other therapeutic areas such as:
Sulfateq consists out of an experienced and dedicated team. On board are internationally known clinicians who work for the University Medical Hospital clinic (UMCG Groningen) and who have extensive experience with clinical trials, especially in kidney diseases. Due to the rapid expansion of the company and developments in the markets we are currently looking for new investors or funding opportunities to develop and expand further business. Are you interested in investing in a breakthrough solution for the prevention of Acute Kidney Injury? Click here for more information!